# Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

> **NCT01893658** · PHASE2 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Acute Interstitial Nephritis

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01893658
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06-01
- **Primary completion:** 2018-09-28
- **Final completion:** 2018-09-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of patients with a condition of interest that resulted in failure to recruit
- **Last updated:** 2018-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893658, "Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01893658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*